Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

New scoring method helps predict functional outcomes in stroke

A new scoring method can help doctors quickly decide which stroke patients will respond well to the clot-busting drug alteplase, according to a study published in the February 7, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

7 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

High beta-amyloid levels may affect brain performance in healthy adults

High levels of the protein beta-amyloid in the brain that is associated with Alzheimer's disease may affect brain performance even in healthy adults, according to a study published in the February 1, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Feb 2012

The Methodist Hospital now offers advanced rehabilitation system for treatment of foot drop

The Methodist Hospital Outpatient Rehabilitation Center now offers an advanced rehabilitation system for the treatment of foot drop in people with mobility issues caused by stroke, traumatic brain injury, multiple sclerosis, cerebral palsy and spinal cord injury.

2 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

Muscle endurance tests can detect abnormalities in early stages of MS

Multiple sclerosis (MS), a neurodegenerative disease, causes periodic attacks of neurologic symptoms such as limb weakness and mobility defects. And while MS patients' walking abilities and muscle strength are examined on a regular basis, doctors have yet to determine when the lower limb muscles begin to deteriorate.

27 Jan 2012

University of Hawaii's ORS to advance employment opportunities for people with disabilities

Kessler Foundation awarded a Signature Employment Grant in the amount of $425,000 to the Office of Research Services at the University of Hawaii, to advance employment opportunities for people with disabilities. The Signature Employment Grant supports the development of a virtual reality (VR) software application, EmployAble: A World Without Barriers, to help jobseekers with disabilities navigate the world of job hunting and adapt to the workplace.

25 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

FDA approves Genzyme's Fabrazyme manufacturing plant in Framingham

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme(agalsidase beta). This follows the previously announced approval by the European Medicines Agency (EMA) last week.

24 Jan 2012

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).

23 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

Memory retraining using mSMT increases cerebral activation in MS patients

Neuroscientists at Kessler Foundation have documented increased cerebral activation in patients with multiple sclerosis (MS) following memory retraining using the modified Story Memory Technique (mSMT).

18 Jan 2012

Converted umbilical cord stem cells hold hope for spinal cord injuries, multiple sclerosis

For the first time ever, stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for spinal cord injuries and multiple sclerosis, among other nervous system diseases.

18 Jan 2012

Defects in mitochondria lead to devastating neurodegenerative disease

A devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk has been traced to defects in mitochondria, the 'batteries' or energy-producing power plants of cells. This finding by a team of researchers, led by investigators from the Montreal Neurological Institute and Hospital - The Neuro- at McGill University, was published in this week's issue of the Proceedings of the National Academy of Sciences of the USA.

18 Jan 2012

EMA approves Genzyme's Fabrazyme manufacturing plant in Framingham

Genzyme, a Sanofi company, announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme.

18 Jan 2012

Vitamin D provides no relief from chronic obstructive pulmonary disease

Earlier studies have suggested that up to three quarters of people with severe chronic obstructive pulmonary disease, or COPD, are deficient in the vitamin. So it was thought that giving them extra vitamin D might help prevent exacerbations in symptoms or trips to the hospital because of shortness of breath or mucus in the airways. Belgian researchers have refuted this claim.

17 Jan 2012

AAN neurologist receives prestigious award at Palatucci Advocacy Leadership Forum

The American Academy of Neurology(AAN) has named neurologist Constantine Moschonas, MD, of Scottsdale, Ariz., as the AAN Donald M. Palatucci Advocacy Leadership Forum Advocate of the Year. Moschonas received his award at the Palatucci Advocacy Leadership Forum on January 14, 2012, in Austin, Texas, for his outstanding work in raising awareness about brain diseases such as Alzheimer's disease, stroke, autism, Parkinson's disease and multiple sclerosis.

17 Jan 2012